Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis
Open Access
- 28 November 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 44 (6) , 1528-1534
Abstract
The diagnosis of an underlying chronic myeloproliferative disorder (CMPD) is often problematic in patients with primary extrahepatic portal vein obstruction (EHPVO) or Budd-Chiari syndrome (BCS); indeed, conventional clinical and hematological parameters usually yield insufficient information. To assess the diagnostic contribution of the gain-of-function mutation V617F of the JAK2 gene, 93 patients with EHPVO or BCS were investigated. JAK2 V617F was identified in 35.6% of 73 patients with EHPVO and in 40% of 20 patients with BCS. Taking the JAK2 mutation as a test with the highest positive predictive value for the diagnosis of CMPD, conventional clinical-hematological parameters had a sensitivity for CMPD lower than 48%. Bone marrow (BM) histology provided a diagnosis of CMPD in 41/74 (55.4%) patients, with a sensitivity of 93.5%. Clonality of hematopoiesis as assessed by granulocyte X-chromosome inactivation was present in 65.1% of 43 informative female patients, with a sensitivity of 86.6%. By resolving the sensitivity bias of the JAK2 mutation with the results of BM histology and clonality assay, CMPD was diagnosed in 53% of patients with EHPVO or BCS. In conclusion , CMPD is the major cause of primary EHPVO or BCS. JAK2 V617F is a very reliable and noninvasive molecular marker for CMPD and should be used as a first test for diagnosis.Keywords
This publication has 28 references indexed in Scilit:
- Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosisBritish Journal of Haematology, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Risk factors for thrombophilia in extrahepatic portal vein obstruction†Hepatology, 2005
- Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: Relationship with splanchnic vein thrombosis and arterial diseaseAmerican Journal of Hematology, 2003
- Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factorsHepatology, 2000
- Spontaneous Erythroid Colony Formation as the Clue to an Underlying Myeloproliferative Disorder in Patients with Budd-Chiari Syndrome or Portal Vein ThrombosisSeminars in Thrombosis and Hemostasis, 1997
- Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 YearsAnnals of Internal Medicine, 1995
- An atypical myeloproliferative disorder with high thrombotic risk and slow disease progressionCancer, 1991
- Erythroid colony growth from peripheral blood and bone marrow in polycythaemia.Journal of Clinical Pathology, 1990
- Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha‐interferonBritish Journal of Haematology, 1990